Price
$140.37-9.22%Social Signal Score
Analyst Ratings
25 analysts52-week range
- Last close
- $140.37
- Off 52w high
- -16.8%
- 200-day average
- $150.19
- vs 200-day
- -6.5%
Revenue
$14.42B+16.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vasant Narasimhan
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 75,267
- Beta
- 0.46
- Country
- CH
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.38
Financials
Revenue
$14.42B+16.8%Net Income
$3.27B+68.4%EBITDA
$5.94B+50.1%Free Cash Flow
$5.57B+147.2%EPS (diluted)
$1.71+111.1%Shares Outstanding (diluted)
1.91B-20.3%Operating Expenses
$6.00BCash & Debt
$7.69BReturn of Capital
$4.06BRevenue by Segment (annual)
$43.27BDividend per Share
$4.74Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.81B | $14.06B | $7.25 |
| 2024 | $51.72B | $11.94B | $5.92 |
| 2023 | $46.66B | $14.85B | $7.15 |
| 2022 | $43.46B | $6.96B | $3.19 |
| 2021 | $43.97B | $24.02B | $10.71 |
| 2020 | $49.90B | $8.07B | $3.54 |
| 2019 | $48.68B | $11.73B | $3.12 |
| 2018 | $46.10B | $12.61B | $5.44 |
| 2017 | $43.40B | $7.70B | $3.28 |
| 2016 | $49.44B | $6.71B | $2.82 |
| 2015 | $50.39B | $17.78B | $7.40 |
| 2014 | $53.63B | $10.21B | $4.21 |
| 2013 | $52.72B | $9.18B | $3.76 |
| 2012 | $51.97B | $9.27B | $3.93 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NVS's reported EPS growth of 4.8% a year over 13 years.
- EPS in 5 years
- $9.16
- Implied price
- $174.12
- Return from $142.57
- 4.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $86.57 — -39.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -5.2% | -12.7% | -9.0% | -5.9% | -3.1% | -0.5% |
| -0.2% | -8.1% | -4.2% | -0.9% | 2.1% | 4.7% |
| 4.8% | -3.5% | 0.6% | 4.1% | 7.2% | 10.0% |
| 9.8% | 1.1% | 5.4% | 9.0% | 12.3% | 15.2% |
| 14.8% | 5.7% | 10.2% | 14.0% | 17.4% | 20.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+60.00%Social Signal Score
Mentions (50)
- Newszacks.com·20h ago·Positive
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
View source ↗ - Newscnbc.com·4d ago·Negative
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks.
View source ↗ - Newswsj.com·4d ago·Negative
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
View source ↗ - Newsreuters.com·4d ago·Negative
Novartis signs mRNA deal for about $7.8 billion with China's Abogen Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
View source ↗ - Newszacks.com·14d ago·Neutral
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
View source ↗ - Newsreuters.com·19d ago·Negative
Novartis halts ALS drug development after mid-stage trial failure Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.
View source ↗ - Newswsj.com·21d ago·Neutral
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
View source ↗ - Newsfool.com·22d ago·Negative
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
View source ↗ - Newsbarrons.com·24d ago·Negative
Novartis: More Pain on the Way? The bad diagnoses just keep on coming for the Swiss drugmaker.
View source ↗ - Newsgurufocus.com·24d ago·Negative
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning Novartis (NVS), the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confi
View source ↗ - Newsreuters.com·25d ago·Negative
Focus: Novartis investors turn spotlight on M&A after trial setbacks Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.
View source ↗ - Newsreuters.com·26d ago·Negative
Major Novartis shareholder calls for board shake-up after drug trial setbacks A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.
View source ↗ - Newszacks.com·26d ago·Neutral
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS) Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen did not meet their respective primary endpoints. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NVS investors.
View source ↗ - Newsseekingalpha.com·27d ago·Neutral
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targeting therapeutic thesis, raising doubts about translating biomarker gains into functional benefit for DYN's DM1 and DMD programs. DYN's lead asset, z-rostudirsen, faces regulatory and confirmatory risks, w
View source ↗ - Newsbenzinga.com·27d ago·Neutral
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
View source ↗ - Newsreuters.com·27d ago·Negative
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
View source ↗ - Newsschaeffersresearch.com·27d ago·Neutral
Novartis Trial Failure Sparks Biopharma Options Frenzy Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector.
View source ↗ - Newsproactiveinvestors.com·27d ago·Negative
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on video hand opening time, a novel measure of hand myotonia that served as the trial's primary endpoint.
View source ↗ - Newsinvestopedia.com·27d ago·Negative
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
View source ↗ - Newsseekingalpha.com·27d ago·Negative
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6% CAGR, aided by Rhapsido's phase 3 success in RMS. Rhapsido's positive data in relapsing multiple sclerosis offer partial offset, with potential for $3 billion+ in annual peak sales.
View source ↗ - Newscnbc.com·27d ago·Negative
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.
View source ↗ - Newsbenzinga.com·28d ago·Neutral
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
View source ↗ - Newsbenzinga.com·28d ago·Positive
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
View source ↗ - Newsinvezz.com·28d ago·Negative
Novartis stock falls 10% after second drug setback in a week; analyst cuts PT Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive future growth. The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions.
View source ↗ - Newscnbc.com·28d ago·Negative
Pharma major plummets over 10% after third trial disappointment in a week Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
View source ↗ - Newsreuters.com·28d ago·Negative
Novartis announces trial setback on del-desiran drug Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran's impact on myotonic dystrophy, a form of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030.
View source ↗ - Newswsj.com·28d ago·Negative
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.
View source ↗ - Newszacks.com·28d ago·Negative
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
View source ↗ - Newswsj.com·29d ago·Negative
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.
View source ↗ - Newsreuters.com·29d ago·Negative
Novartis shares down as failed cholesterol drug study increases pipeline pressure Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker's upcoming data for a gene therapy.
View source ↗ - Newsbarrons.com·30d ago·Negative
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares? In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
View source ↗ - Newswsj.com·31d ago·Negative
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a comp
View source ↗ - Newswsj.com·31d ago·Negative
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.
View source ↗ - Newsreuters.com·31d ago·Negative
Ionis, Novartis' key experimental heart drug fails in late-stage trial Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocard
View source ↗ - Newsproactiveinvestors.co.uk·32d ago·Neutral
RBC backs Oxford BioMedica with 'outperform' rating amid Novartis trial halt Oxford BioMedica PLC (LSE:OXB) received a reaffirmed 'outperform' rating from RBC Capital Markets on Friday, as the broker shrugged off clinical trial halts at two heavyweight pharmaceutical partners. The shares inched up 1% to 430p in morning trade, with RBC holding its 900p target price and branding the clinical disruption as of limited direct financial relevance.
View source ↗ - News247wallst.com·32d ago·Positive
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One Novartis just committed billions not to discover a new drug but to change how an existing one enters your body.
View source ↗ - Newszacks.com·33d ago·Negative
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
View source ↗ - Newsreuters.com·33d ago·Negative
Novartis could cut about 130 jobs in Basel site relocation Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday.
View source ↗ - Newsproactiveinvestors.co.uk·34d ago·Positive
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their autoimmune CAR-T programmes following safety issues.
View source ↗ - Newsinvestopedia.com·34d ago·Negative
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping Promising results from a recent clinical trial are boosting Novartis shares this morning.
View source ↗ - Newsbarrons.com·35d ago·Positive
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
View source ↗ - Newsbarrons.com·35d ago·Negative
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
View source ↗ - Newswsj.com·35d ago·Negative
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.
View source ↗ - Newsreuters.com·35d ago·Negative
Novartis' oral multiple sclerosis drug meets main goal in late stage studies Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
View source ↗ - Newsreuters.com·35d ago·Positive
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesday.
View source ↗ - Newswsj.com·35d ago·Positive
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
View source ↗ - News247wallst.com·48d ago·Neutral
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $2.24 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$2.41 vs $2.17beat
- Tue, Apr 28$1.99 vs $2.11miss
- Wed, Feb 4$2.03 vs $1.99beat
- Tue, Oct 28$2.25 vs $2.26miss
- Thu, Jul 17$2.42 vs $2.38beat
- Tue, Apr 29$2.28 vs $2.12beat
Estimates and results for NVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (32d later)Sell$15,001 - $50,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (64d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$100,001 - $250,000
- Sheldon Whitehousesenate · RI · disclosed May 20, 2024 (41d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (26d later)Buy$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Oct 17, 2023 (27d later)Buy$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
- Thomas Richard Carpersenate · DE · disclosed May 1, 2023 (5d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Buy$50,001 - $100,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.